RxDoctor Payments DataLook up a doctor →

Anne Winkler, MD

Rheumatology · Carthage, MONPI 1346307220

Payments from drug & device makers

$1,630,618in general payments, 2019–2025

Across 2,410 payments — averaging $676.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$477K
  • UCB, Inc.$159K
  • AstraZeneca$127K
  • Lilly USA, LLC$113K
  • Amgen$99K
  • Aurinia Pharma U.S., Inc.$99K
  • plus $556K from 16 others

What the payments were for

  • Consulting fees$168,89110%
  • Speaking & faculty fees$1,202,78174%
  • Travel & lodging$214,07613%
  • Food & beverage$41,4853%
  • Education$8710%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,630,618 in reported general payments places this provider in the 95th percentile of 134 rheumatology providers in Missouri.

See all rheumatology providers in Missouri

Medicare billing

Part B allowed, 2024
$24,029
Medicare patients
146
Services billed
449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab112$1,095,310
RinvoqUpadacitinib97$707,300
Enbrel SureclickEtanercept45$331,961
Xeljanz XrTofacitinib Citrate56$325,535
OrenciaAbatacept46$266,110
EnbrelEtanercept20$178,703
OtezlaApremilast28$134,286
Taltz AutoinjectorIxekizumab12$113,231
Cosentyx Sensoready (2 Pens)Secukinumab11$92,346
Humira(Cf)Adalimumab13$88,550
XeljanzTofacitinib Citrate13$84,500
OxycontinOxycodone Hcl44$40,723
Hydroxychloroquine Sulfate732$22,877
MethotrexateMethotrexate Sodium682$13,172
Leflunomide201$8,463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$476,811$795,849110 claims
AmgenEnbrel, Otezla$99,410$312,98948 claims
E.r. Squibb & Sons, L.L.C.Orencia$231$266,11046 claims
PfizerXeljanz$70,128$84,50013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 134 rheumatology providers in Missouri.

Other rheumatology in Carthage

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →